LifeMine Therapeutics is pioneering a genomically-enabled drug discovery approach integrating advanced life science and computational technologies to elucidate human biology and create sophisticated therapeutics that attack the fundamental drivers of serious human diseases.
LifeMine will access new drug modalities by conducting the first industrial-scale operation exploiting small molecule evolution in fungi to discover game-changing therapeutics. The initial focus will be on immune modulators, metabolic effectors, and cell differentiators. This platform is expected to provide multiple first- and best-in-class therapeutics in succession, and to continue delivering these for years to come.
Founder & CEO: Greg Verdine, Erving Professor at Harvard University and Harvard Medical School. Founder of Gloucester Pharmaceuticals (acquired by Celgene), Enanta Pharmaceuticals (NASDAQ: ENTA), Eleven Biotherapeutics (NASDAQ: EBIO), Tokai Pharmaceuticals (NASDAQ: TKAI), WaVe Life Sciences (NASDAQ: WVE), Warp Drive Bio, Aileron Therapeutics, and the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $280M
Founded date: 2017
Investors 5
Date | Name | Website |
- | Foresite C... | foresiteca... |
17.07.2021 | ARCH Ventu... | archventur... |
- | 6 Dimensio... | 6dimension... |
- | MRL Ventur... | mrlv.com |
- | GV | gv.com |
Funding Rounds 3
Date | Series | Amount | Investors | Deal News |
15.04.2022 | Series C | $175M | - | vcnewsdail... |
07.01.2021 | Series B | $50M | - | citybizlis... |
18.09.2017 | Series A | $55M | ARCH Ventu... | finsmes.co... |
Mentions in press and media 10
Date | Title | Description | Source |
23.03.2022 | LifeMine Therapeutics Snags $175M in Series C | CAMBRIDGE, MA, LifeMine Therapeutics, a biopharmaceutical company, announced the completion of a $... | vcnewsdail... |
07.01.2021 | LifeMine Therapeutics Raises $50 Million Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--LifeMine Therapeutics Inc., a biopharmaceutical company reinventi... | citybizlis... |
07.01.2021 | LifeMine Therapeutics Announces $50 Million Series B Financi... | LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal ... | marketscre... |
16.05.2018 | FogPharma Secures $66 Million Series B Financing | FogPharma today announced the closing of a $66 millionSeries B financing. The round was led by 6 Dim... | citybizlis... |
19.09.2017 | Term Sheet — Tuesday, September 19 | VCs VERSUS ICOs Companies have raised more than $1.7 billion through initial coin offerings this ye... | fortune.co... |
19.09.2017 | China’s Wuxi Healthcare Ventures leads $55m Series A in US-b... | Premium Chinese investment firm Wuxi Healthcare Ventures has led a $55-million series A financing f... | dealstreet... |
18.09.2017 | Arch Ventures Joins $55M Series A for LifeMine Therapeutics | LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was... | citybizlis... |
18.09.2017 | LifeMine Therapeutics Launches with $55M Series A | BOSTON, MA, LifeMine Therapeutics today announced the closing of a $55 million Series A financing.... | vcnewsdail... |
18.09.2017 | LifeMine Therapeutics Closes $55M Series A Financing | LifeMine Therapeutics, a Boston, MA-based drug discovery company, closed a $55m Series A financing. ... | finsmes.co... |
18.09.2017 | LifeMine Therapeutics Closes $55M Series A | LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was... | citybizlis... |